2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2864

Anti-Acetylated Peptide Antibodies Positive Rheumatoid Arthritis Patients Show a More Favorable Response to Tumor-Necrosis-Factor Inhibitor Treatment and Better Disease Activity Control over Time
Abstract Number: 685

Anti-C1q Antibodies and Disease Activity in a Multi-Ethnic Lupus Cohort
Abstract Number: 480

ANTI-Carbamylated Protein Antibodies (CARP) in Palindromic Rheumatism: Prevalence and Clinical Significance
Abstract Number: 2914

Anti-CCP Antibody Levels Are Elevated in Cervicovaginal Fluid in Association with Local Inflammation in Premenopausal Women without RA
Abstract Number: 486

Anti-Citrullinated Protein Antibody Reactivities in Treatment NaïVe Early Rheumatoid Arthritis
Abstract Number: 2145

Anti-CXCR3 Antibody Suppresses Inflammation in C Protein-Induced Myositis Model
Abstract Number: 1357

Anti-Cyclic Citrullinated Peptide Antibody Positive Rheumatoid Arthritis Patients with Comorbid Post-Traumatic Stress Disorder Have Higher Serum Cytokine Expression
Abstract Number: 1927

Anti-Fibrotic Mechanisms of Endostatin-Derived Peptide Are the Result of Reduction in Pro-Fibrotic Mediators and Promotion of Extracellular Matrix Degradation
Abstract Number: 397

Anti-Fractalkine Monoclonal Antibody Ameliorates Joint Destruction in Collagen-Induced Arthritis Model through Suppression of Osteoclast Precursor Cell Survival and Migration
Abstract Number: 2721

Anti-IL6-Receptor Tocilizumab in Refractory Uveitis Associated to Extraocular Manifestations in Patients with Behçet’s Disease. Multicenter Study
Abstract Number: 1949

Anti-Inflammatory Effects of Standardized Platelet-Rich Plasma Releasates in Knee and Hip OA Chondrocytes
Abstract Number: 2901

Anti-Inflammatory Mechanism of Lubricin/Proteoglycan 4 (PRG4) in Monosodium Urate (MSU)-Crystal Induced Arthritis in THP-1 Macrophages Is Mediated By NALP3 Inflammasome.
Abstract Number: 1274

Anti-MDA5 Autoantibodies Associated with Juvenile Dermatomyositis Constitute a Distinct Phenotype in North America
Abstract Number: 1669

Anti-Mitochondria DNA Antibody As an Improved Biomarker for Systemic Lupus Erythematosus
Abstract Number: 1666

Anti-Mitochondrial Autoantibodies in Systemic Lupus Erythematosus and Their Association with Disease Manifestations

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].